Premenstrual Syndrome Symptomatology Among Married Women of Fertile Age Based on Methods of Contraception (hormonal Versus Non-hormonal Methods of Contraception)

Overview

Journal Glob J Health Sci

Specialties General Medicine
Public Health

Date 2014 Mar 1

PMID 24576370

Citations 6

Authors

Nour Mohammad Bakhshani

Mohsen Hosseinbor

Zahra Shahraki

Nahid Sakhavar

Affiliations

Soon will be listed here.

Abstract

Introduction: Premenstrual syndrome (PMS) refers to the cyclic occurrence of a set of disturbing physical, emotional or behavioral alterations that are of sufficient severity to interfere with interpersonal relations and routine life. Normal variations in gonadal estrogen and progesterone lead to biochemical reactions in the brain, resulting in PMS symptoms. This study aims to investigate the prevalence of PMS and PMDD signs among married women of fertile age (MWFA) based on the methods of birth control.

Method And Materials: In a descriptive study, a number of 400 married women referring to 20 family healthcare clinics that use contraceptive methods were recruited and PMS questionnaire were administered to them.

Results: From 400 subjects, 205 took oral contraceptive pills (hormonal methods of contraception) and 195 used other birth control methods (non-hormonal method). A number of 345 subjects (86.25%) at least experienced one PMS symptom and 55 subjects (13.75%) did not report any symptoms. Of those who use hormonal contraceptives (HCs), 182 (88.8%) reported PMS symptoms and 23(11.2) lacked any symptoms.

Conclusion: About 86% of the subjects showed moderate to severe of PMS symptoms. Although using hormonal contraceptive method can theoretically reduce PMS symptoms, such effect was not observed in this study. The results of this research should be generalized with caution. Future studies are suggested.

Citing Articles

Management of a Patient With Premenstrual Syndrome Using Acupuncture, Supplements, and Meditation: A Case Report.

Martin B, Woodruff J J Chiropr Med. 2023; 22(3):222-229.

PMID: 37644997 PMC: 10461168. DOI: 10.1016/j.jcm.2023.03.006.

Lowered Plasma Steady-State Levels of Progesterone Combined With Declining Progesterone Levels During the Luteal Phase Predict Peri-Menstrual Syndrome and Its Major Subdomains.

Roomruangwong C, Carvalho A, Comhaire F, Maes M Front Psychol. 2019; 10:2446.

PMID: 31736837 PMC: 6831719. DOI: 10.3389/fpsyg.2019.02446.

Leon-Larios F, Vazquez-Valeo C, Sanchez-Sanchez A, Gomez-Baya D, Macias-Seda J, Cabezas-Palacios M Health Qual Life Outcomes. 2019; 17(1):90.

PMID: 31126343 PMC: 6534913. DOI: 10.1186/s12955-019-1157-2.

Premenstrual syndrome in Anand District, Gujarat: A cross-sectional survey.

Kamat S, Nimbalkar A, Phatak A, Nimbalkar S J Family Med Prim Care. 2019; 8(2):640-647.

PMID: 30984687 PMC: 6436252. DOI: 10.4103/jfmpc.jfmpc_302_18.

Hormonal contraceptive use and prevalence of premenstrual symptoms in a multiethnic Canadian population.

Jarosz A, Jamnik J, El-Sohemy A BMC Womens Health. 2017; 17(1):87.

PMID: 28950854 PMC: 5615478. DOI: 10.1186/s12905-017-0450-7.

References

Tschudin S, Bertea P, Zemp E . Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010; 13(6):485-94. DOI: 10.1007/s00737-010-0165-3. View

Johnson T . Premenstrual syndrome as a western culture-specific disorder. Cult Med Psychiatry. 1987; 11(3):337-56. DOI: 10.1007/BF00048518. View

Dean B, Borenstein J, Knight K, Yonkers K . Evaluating the criteria used for identification of PMS. J Womens Health (Larchmt). 2006; 15(5):546-55. DOI: 10.1089/jwh.2006.15.546. View

Backstrom T, LINDHE B, Nordenstrom S . Oral contraceptives in premenstrual syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 1992; 46(3):253-68. DOI: 10.1016/0010-7824(92)90006-f. View

Freeman E . Premenstrual syndrome and premenstrual dysphoric disorder: definitions and diagnosis. Psychoneuroendocrinology. 2003; 28 Suppl 3:25-37. DOI: 10.1016/s0306-4530(03)00099-4. View

Sadler C, Smith H, Hammond J, Bayly R, Borland S, Panay N . Lifestyle factors, hormonal contraception, and premenstrual symptoms: the United Kingdom Southampton Women's Survey. J Womens Health (Larchmt). 2010; 19(3):391-6. PMC: 3091016. DOI: 10.1089/jwh.2008.1210. View

Sampson G . Premenstrual syndrome: a double-blind controlled trial of progesterone and placebo. Br J Psychiatry. 1979; 135:209-15. DOI: 10.1192/bjp.135.3.209. View

Ford O, Lethaby A, Mol B, Roberts H . Progesterone for Premenstrual Syndrome. Cochrane Database Syst Rev. 2006; (4):CD003415. DOI: 10.1002/14651858.CD003415.pub2. View

Calhoun A . Menstrual migraine: update on pathophysiology and approach to therapy and management. Curr Treat Options Neurol. 2011; 14(1):1-14. DOI: 10.1007/s11940-011-0153-6. View

10.

Bakhshani N, Mousavi M, Khodabandeh G . Prevalence and severity of premenstrual symptoms among Iranian female university students. J Pak Med Assoc. 2009; 59(4):205-8. View

11.

Dennerstein L, Gotts G, Brown J, Smith M, Burrows G . Progesterone and the premenstrual syndrome: a double blind crossover trial. Br Med J (Clin Res Ed). 1985; 290(6482):1617-21. PMC: 1415816. DOI: 10.1136/bmj.290.6482.1617. View

12.

Anson O . Exploring the bio-psycho--social approach to premenstrual experiences. Soc Sci Med. 1999; 49(1):67-80. DOI: 10.1016/s0277-9536(99)00079-9. View

13.

Diegoli M, da Fonseca A, Diegoli C, PINOTTI J . A double-blind trial of four medications to treat severe premenstrual syndrome. Int J Gynaecol Obstet. 1998; 62(1):63-7. DOI: 10.1016/s0020-7292(98)00035-6. View

14.

Potter J, Bouyer J, Trussell J, Moreau C . Premenstrual syndrome prevalence and fluctuation over time: results from a French population-based survey. J Womens Health (Larchmt). 2008; 18(1):31-9. PMC: 3196060. DOI: 10.1089/jwh.2008.0932. View

15.

Sulak P . Ovulation suppression of premenstrual symptoms using oral contraceptives. Am J Manag Care. 2005; 11(16 Suppl):S492-7. View

16.

Hourani L, Yuan H, Bray R . Psychosocial and lifestyle correlates of premenstrual symptoms among military women. J Womens Health (Larchmt). 2004; 13(7):812-21. DOI: 10.1089/jwh.2004.13.812. View

17.

Freeman E, Kroll R, Rapkin A, Pearlstein T, Brown C, Parsey K . Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder. J Womens Health Gend Based Med. 2001; 10(6):561-9. DOI: 10.1089/15246090152543148. View

18.

Sulak P, Kuehl T, Coffee A, Willis S . Prospective analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. Am J Obstet Gynecol. 2006; 195(4):935-41. DOI: 10.1016/j.ajog.2006.02.048. View

19.

Usman S, Indusekhar R, OBrien S . Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol. 2007; 22(2):251-60. DOI: 10.1016/j.bpobgyn.2007.07.001. View

20.

Coffee A, Kuehl T, Willis S, Sulak P . Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen. Am J Obstet Gynecol. 2006; 195(5):1311-9. DOI: 10.1016/j.ajog.2006.05.012. View